Protara Therapeutics, Inc. (FRA:1KPA)

Germany flag Germany · Delayed Price · Currency is EUR
5.15
-0.55 (-9.65%)
Last updated: Dec 5, 2025, 8:06 AM CET
116.39%
Market Cap 227.32M
Revenue (ttm) n/a
Net Income (ttm) -45.09M
Shares Out n/a
EPS (ttm) -1.18
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 388
Average Volume 23
Open 5.15
Previous Close 5.70
Day's Range 5.15 - 5.15
52-Week Range 2.26 - 9.15
Beta n/a
RSI 55.90
Earnings Date Mar 9, 2026

About Protara Therapeutics

Protara Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in advancing transformative therapies for the treatment of cancer and rare diseases. The company’s lead program is TARA-002, an investigational cell therapy, which is in Phase II clinical trial for the treatment of non-muscle invasive bladder cancer and lymphatic malformations. It is also developing intravenous choline chloride, an investigational phospholipid substrate replacement therapy for patients receiving parenteral nutrition and fluids. The company is headqu... [Read more]

Industry Biological Products, Except Diagnostic Substances
CEO Jesse Shefferman
Employees 33
Stock Exchange Frankfurt Stock Exchange
Ticker Symbol 1KPA
Full Company Profile

Financial Performance

Financial numbers in USD Financial Statements

News

There is no news available yet.